The Supreme Court is gearing up to make a crucial decision on the federal government's approval process of the drug mifepristone, which is used for terminating pregnancies. This case, set for oral arguments on Tuesday, carries significant legal, social, and political implications, especially in the realm of reproductive rights.
New data from the Guttmacher Institute reveals that nearly two-thirds of all abortions in the U.S. in 2023 relied on mifepristone. Abortion rights advocates argue that the drug is safe and that any adverse ruling could impact millions of women nationwide. Conversely, anti-abortion groups claim that the FDA has been unlawfully promoting on-demand abortion for years.
